Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer.

Fizazi, Karim; Bernard-Tessier, Alice; Roubaud, Guilhem; Utriainen, Tapio; Barthélémy, Philippe; Fléchon, Aude; van der Voet, Johannes; Gravis, Gwenaëlle; Ratta, Raffaele; Jones, Robert; Parikh, Omi; Tanner, Minna; Antonarakis, Emmanuel S; Baldini, Capucine; Peters, Niamh; Garratt, Chris; Ikonen, Tarja; Pohjanjousi, Pasi; Joensuu, Heikki; Cook, Natalie

Fizazi, Karim; Bernard-Tessier, Alice; Roubaud, Guilhem; Utriainen, Tapio; Barthélémy, Philippe; Fléchon, Aude; van der Voet, Johannes; Gravis, Gwenaëlle; Ratta, Raffaele; Jones, Robert; Parikh, Omi; Tanner, Minna; Antonarakis, Emmanuel S; Baldini, Capucine; Peters, Niamh; Garratt, Chris; Ikonen, Tarja; Pohjanjousi, Pasi; Joensuu, Heikki; Cook, Natalie.

Affiliation

Fizazi K; Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France.
Bernard-Tessier A; Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France.
Roubaud G; Medical Oncology, Institut Bergonié, Bordeaux, France.
Utriainen T; Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.
Barthélémy P; Institut de Cancérologie Strasbourg Europe, Strasbourg, France.
Fléchon A; Medical Oncology, Centre Léon Bérard, Lyon, France.
van der Voet J; Radiotherapy, The James Cook University Hospital, Middlesbrough, United Kingdom.
Gravis G; Medical Oncology, Institut Paoli-Calmettes, Marseille, France.
Ratta R; Medical Oncology, Hôpital Foch, Suresnes, France.
Jones R; Cardiff University and Velindre University National Health Service Trust, Cardiff, United Kingdom.
Parikh O; Oncology, Royal Preston Hospital-Lancashire Teaching Hospitals National Health Service Foundation Trust, Preston, United Kingdom.
Tanner M; R&D, Tampere University Hospital, Tampere, Finland.
Antonarakis ES; Department of Medicine, University of Minnesota Masonic Cancer Center, Minneapolis.
Baldini C; Drug Development Department, Université Paris-Saclay, Gustave Roussy, Villejuif, France.
Peters N; University of Manchester and the Christie National Health Service Foundation Trust, Manchester, United Kingdom.
Garratt C; Orion Corporation, Orion Pharma, Espoo, Finland.
Ikonen T; Orion Corporation, Orion Pharma, Espoo, Finland.
Pohjanjousi P; Orion Corporation, Orion Pharma, Espoo, Finland.
Joensuu H; Orion Corporation, Orion Pharma, Espoo, Finland.
Cook N; University of Manchester and the Christie National Health Service Foundation Trust, Manchester, United Kingdom.

NEJM Evid ; 3(1): EVIDoa2300171, 2024 Jan.

Article de En | MEDLINE | ID: mdl-38320513

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Récepteurs aux androgènes / Tumeurs prostatiques résistantes à la castration Type d'étude: Clinical_trials Limites: Humans / Male Langue: En Journal: NEJM Evid Année: 2024 Type de document: Article Pays d'affiliation: France Pays de publication: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google